Anavex Lf SC (AVXL)

$5.01 +0.16 (3.30%)
Market Cap 433.34M
Revenue (ttm) 0.00
Net Income (ttm) -46.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,735,900
Avg Vol 3,044,400
Day's Range N/A - N/A
Shares Out 89.35M
Stochastic %K 85%
Beta 1.17
Analysts Sell
Price Target $22.00

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-c...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 689 3939
Address:
630 5th Avenue, 20th Floor, New York, United States
Series4Guy
Series4Guy Jan. 17 at 6:28 PM
$AVXL Here’s something else to like about ACCESS-AD… Heightened awareness of Blarcamesine in media, conferences, academia, science, synergies, and investments over the next 5 years! As our participation will mean phased outputs (e.g., framework validations, AI/biomarker tools) all referencing Blarcamesine. Free publicity, awareness and marketing!
0 · Reply
imatrader65
imatrader65 Jan. 17 at 3:23 PM
Something to think about over long weekend. $AVXL
3 · Reply
Plexrec
Plexrec Jan. 17 at 2:29 PM
$AVXL Anyone ? When do we find out that the EMA has accepted our request for re-examination ????
2 · Reply
Plexrec
Plexrec Jan. 17 at 12:33 PM
$AVXL Only "up" days thus far in '26---11 in a row--not big numbers but good to see. (hope I don't jinx this run"
0 · Reply
a1p
a1p Jan. 17 at 12:18 PM
$AVXL long and strong
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 17 at 9:35 AM
Enter: $AVXL Calls Strike Price: $6 Expiry Date: FEB 20 2026 Buy in Price: $0.29 - $0.35 Sell Price: $0.57 Profit : +96% (Turn every $1 into $1.96) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
BulICrunch
BulICrunch Jan. 17 at 6:46 AM
$AVXL what’s your guys averages? And long term predictions
3 · Reply
Run1246
Run1246 Jan. 17 at 1:17 AM
$AVXL all the longs who sold are now bashers? lol while you have been living under a rock a lot has happened in the last couple weeks.
4 · Reply
badprecog
badprecog Jan. 17 at 12:51 AM
$AVXL FDA approval in AD = 25b min. Odds of NDA accepted to approval = 70 percent. Anavex had a type C meeting with FDA where there is a path forward to an NDA… so basically we are submitting an NDA… MC $400 million????? We should be at $50 percent share without EMA. Just buy and hold… our day is coming soon!!!
2 · Reply
dtsguy13
dtsguy13 Jan. 17 at 12:16 AM
$AVXL Ready for some more green days ahead! Enjoy your long weekend! Forever
0 · Reply
Latest News on AVXL
Anavex Life Sciences Corp. (AVXL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 10:15 PM EST - 2 days ago

Anavex Life Sciences Corp. (AVXL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease

Jan 13, 2026, 7:30 AM EST - 4 days ago

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

Jan 8, 2026, 7:30 AM EST - 9 days ago

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program

Jan 6, 2026, 7:30 AM EST - 11 days ago

Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Dec 24, 2025, 10:30 AM EST - 24 days ago

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Dec 18, 2025, 7:30 AM EST - 4 weeks ago

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease

Dec 12, 2025, 4:05 PM EST - 5 weeks ago

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 26, 2025, 7:30 AM EST - 7 weeks ago

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call Transcript

Nov 25, 2025, 11:53 AM EST - 7 weeks ago

Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call Transcript

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Nov 25, 2025, 7:30 AM EST - 7 weeks ago

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Nov 19, 2025, 7:30 AM EST - 2 months ago

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Nov 18, 2025, 7:30 AM EST - 2 months ago

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Nov 14, 2025, 7:30 AM EST - 2 months ago

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group

Oct 29, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'

Oct 10, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'

Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia

Oct 2, 2025, 1:40 PM EDT - 3 months ago

Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Oct 2, 2025, 7:35 AM EDT - 3 months ago

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Oct 2, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial

Sep 30, 2025, 8:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

Sep 9, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Sep 2, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Aug 26, 2025, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

Aug 20, 2025, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript

Aug 12, 2025, 10:38 AM EDT - 5 months ago

Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Aug 12, 2025, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Aug 5, 2025, 7:30 AM EDT - 5 months ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Does Anavex's Alzheimer's Drug Actually Confer Benefit?

May 15, 2025, 8:49 PM EDT - 8 months ago

Does Anavex's Alzheimer's Drug Actually Confer Benefit?

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

May 15, 2025, 12:21 PM EDT - 8 months ago

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 14, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

May 13, 2025, 9:25 AM EDT - 8 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 6, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

May 1, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 30, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 23, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 21, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Apr 5, 2025, 11:30 AM EDT - 10 months ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:30 AM EDT - 10 months ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 7:30 AM EST - 11 months ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Feb 14, 2025, 6:02 PM EST - 1 year ago

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Feb 12, 2025, 3:13 PM EST - 1 year ago

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Feb 12, 2025, 9:59 AM EST - 1 year ago

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 12, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Feb 5, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Jan 27, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Jan 15, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Series4Guy
Series4Guy Jan. 17 at 6:28 PM
$AVXL Here’s something else to like about ACCESS-AD… Heightened awareness of Blarcamesine in media, conferences, academia, science, synergies, and investments over the next 5 years! As our participation will mean phased outputs (e.g., framework validations, AI/biomarker tools) all referencing Blarcamesine. Free publicity, awareness and marketing!
0 · Reply
imatrader65
imatrader65 Jan. 17 at 3:23 PM
Something to think about over long weekend. $AVXL
3 · Reply
Plexrec
Plexrec Jan. 17 at 2:29 PM
$AVXL Anyone ? When do we find out that the EMA has accepted our request for re-examination ????
2 · Reply
Plexrec
Plexrec Jan. 17 at 12:33 PM
$AVXL Only "up" days thus far in '26---11 in a row--not big numbers but good to see. (hope I don't jinx this run"
0 · Reply
a1p
a1p Jan. 17 at 12:18 PM
$AVXL long and strong
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 17 at 9:35 AM
Enter: $AVXL Calls Strike Price: $6 Expiry Date: FEB 20 2026 Buy in Price: $0.29 - $0.35 Sell Price: $0.57 Profit : +96% (Turn every $1 into $1.96) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
BulICrunch
BulICrunch Jan. 17 at 6:46 AM
$AVXL what’s your guys averages? And long term predictions
3 · Reply
Run1246
Run1246 Jan. 17 at 1:17 AM
$AVXL all the longs who sold are now bashers? lol while you have been living under a rock a lot has happened in the last couple weeks.
4 · Reply
badprecog
badprecog Jan. 17 at 12:51 AM
$AVXL FDA approval in AD = 25b min. Odds of NDA accepted to approval = 70 percent. Anavex had a type C meeting with FDA where there is a path forward to an NDA… so basically we are submitting an NDA… MC $400 million????? We should be at $50 percent share without EMA. Just buy and hold… our day is coming soon!!!
2 · Reply
dtsguy13
dtsguy13 Jan. 17 at 12:16 AM
$AVXL Ready for some more green days ahead! Enjoy your long weekend! Forever
0 · Reply
Georgejj
Georgejj Jan. 16 at 11:39 PM
$AVXL "...APOE4 carriers have a higher Alzheimer's risk, and while amyloid-targeting monoclonal antibodies (mAbs) like lecanemab can work, they increase risks for ARIA (brain swelling/bleeding)..." Good luck and GOD bless,
0 · Reply
Georgejj
Georgejj Jan. 16 at 11:19 PM
$AVXL From this latest patent: "...These results demonstrated that blarcamesine was more efficacious or effective in APOE4-carriers than in APOE4-noncarriers...." Good luck and GOD bless,
0 · Reply
Georgejj
Georgejj Jan. 16 at 10:59 PM
$AVXL From this latest patent: "...These results demonstrated that blarcamesine was more efficacious or effective in APOE4-carriers than in APOE4-noncarriers...." Good luck and GOD bless,
0 · Reply
DarthWallstreet
DarthWallstreet Jan. 16 at 10:43 PM
$AVXL Jumped in yesterday, will keep adding up. Big upside!
2 · Reply
45bulls
45bulls Jan. 16 at 10:06 PM
$AVXL https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2026015656&_cid=P12-MKHF14-17401-7
2 · Reply
Georgejj
Georgejj Jan. 16 at 9:48 PM
$AVXL A BRAND NEW WORLD PATENT https://patentscope.wipo.int/search/en/result.jsf?_vid=P20-MKHD29-01617 Good luck and GOD bless,
2 · Reply
rando_on_the_internet
rando_on_the_internet Jan. 16 at 9:17 PM
$AVXL "As Anavex reports, the CHMP has already indicated that for a possible (conditional) approval under a re-examination, biomarker data may be relevant that show a direct link between a slowing of cognitive decline and brain atrophy as a surrogate endpoint."
1 · Reply
gldncrss
gldncrss Jan. 16 at 9:11 PM
$AVXL was expecting a stronger closing oh well wait for Monday
2 · Reply
Nephro
Nephro Jan. 16 at 8:27 PM
$AVXL in a few weeks we find out what the institutions did / hold as of Dec 31 st 🤞
1 · Reply
Series4Guy
Series4Guy Jan. 16 at 8:24 PM
$AVXL
0 · Reply
old_salt
old_salt Jan. 16 at 8:09 PM
$AVXL https://www.marketbeat.com/instant-alerts/d-boral-capital-reaffirms-buy-rating-for-anavex-life-sciences-nasdaqavxl-2026-01-06/
1 · Reply
Fraser100
Fraser100 Jan. 16 at 8:06 PM
$AVXL Maybe I missed the memo. When Blarcamesine was rejected by the CHMA (or EMA) was a formal statement released giving the rationale for this rejection?
2 · Reply